New drug cocktail aims to tackle lymphoma without chemo

NCT ID NCT04792502

Recruiting now Disease control Sponsor: Brown University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study is testing two drugs, mosunetuzumab and lenalidomide, as the first treatment for people with follicular or marginal zone lymphoma. Participants start with mosunetuzumab alone, and those who only partially respond get lenalidomide added. The goal is to see how many achieve a complete response after eight cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mosunetuzumab and lenalidomide
What this could lead to: If successful, this combination could offer a new first-line treatment option for people with follicular or marginal zone lymphoma, potentially improving complete response rates.
What could go wrong: This is an early-phase, single-arm trial with only 52 participants, so results may not apply broadly. Side effects from the drugs, such as immune reactions or blood issues, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm follicular lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA FOLLICULAR LYMPHOMA MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

Lifespan Cancer Insitute
RECRUITING

Providence, Rhode Island, 02903, United States
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States
Yale Cancer Center
NOT_YET_RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.